Characterization of HBV DNA +/HBsAg - blood donors in Poland identified by triplex NAT

Ewa Brojer, Piotr Grabarczyk, Grzegorz Liszewski, Maria Mikulska, Jean Pierre Allain, Magdalena Letowska, D. Kubicka-Russel, A. Kopacz, A. Gronowska, B. Boczkowska-Radziwon, M. Dobrowolna, B. Zalewicz, B. Wyrwińska, M. Tarnawska, S. Dyla̧g, Z. Sitarz-Zelazna, J. Kuśmierczyk, J. Raś, H. Radwan-Wieczorek, J. KorzeniowskaB. Sȩkowska, A. Rumas, G. Kula, I. Rajca-Biernacka, M. Krug-Janiak, J. Kulbaka-Myrczek, H. Kaczor, A. Krygowska, A. Dobrecka, D. Stȩpień-Razzu, A. ŚWider-Michalska, U. Zarówna, J. Gawȩda, D. Malka, E. Świa̧tek, M. Fabisz-Kołodzińiska

Research output: Contribution to journalArticlepeer-review

95 Scopus citations


Nucleic acid testing (NAT) for hepatitis B virus (HBV) has been performed in Poland since 2005 on samples seronegative for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), and anti-human immunodeficiency virus (anti-HIV). Tools included 24-donation pool testing (PT) using Cobas Amplicor or in individual donations (ID) by Procleix Ultrio. Seven of 761,666 (1:108,800) and 21/250,191 (1:11,900) HBV DNA-positive donations were identified and confirmed by alternative methods. HBV DNA load ranged between 11.6 and 4.6 × 10 4 IU/mL in 11 samples and could not be quantified in 17 samples. HBV genotypes A (56%) and D (4%) were found. The analysis of combined results from index, follow-up, and look-back samples identified four groups: (1) Two cases tested HBsAg positive with alternative, more sensitive, assays; (2) Four cases were in the pre-seroconversion window period; (3) Eight cases had a fluctuating pattern of HBV DNA and anti-HBs detection (recovered infection); and (4) twelve cases carried anti-HBc without anti-HBs, which might correspond to either chronic or recovered "occult" HBV infection. One donor with no HBV markers in the follow-up was excluded, and another was in the window period preceding anti-HBs. HBV NAT identified more confirmed positive donors than HCV or HIV NAT, and 1:250,000 could not be detected by anti-HBc screening. Serological and molecular studies on follow-up and look-back samples are important to classify donors. In conclusion, further studies are needed to determine whether the considerably higher yield of HBV DNA detection obtained with individual donation screening improves blood safety compared with anti-HBc screening.

Original languageEnglish
Pages (from-to)1666-1674
Number of pages9
Issue number6
StatePublished - Dec 2006
Externally publishedYes


Dive into the research topics of 'Characterization of HBV DNA +/HBsAg - blood donors in Poland identified by triplex NAT'. Together they form a unique fingerprint.

Cite this